High thrombotic risk in cancer patients receiving immunotherapy

(Medical University of Vienna) In a study recently published in the leading journal " Blood " , researchers at MedUni Vienna provided preliminary data on the incidence, risk factors and clinical outcomes of thrombotic complications in this new form of cancer treatment. The main finding is that, during the course of treatment, approximately 13% of patients develop a venous thromboembolism, that is to say a deep vein thrombosis or pulmonary embolism, and approximately 2% develop a thrombosis in the arterial system.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news